Oppenheimer began its coverage of Pacira BioSciences, Inc. (NASDAQGS:PCRX) (DB:82P) on September 23, 2026, assigning the stock an Outperform rating.
Pacira BioSciences is a U.S.-based pharmaceutical company focused on developing, manufacturing and commercializing non-opioid pain-management and regenerative-health solutions. Its EXPAREL product is a liposomal injection of the anesthetic bupivacaine, designed to provide prolonged pain relief after surgery without opioids. The company is working to expand the use of its proprietary therapies through clinical trials and partnerships intended to improve post-surgical pain treatment and patient outcomes.
Pacira shares closed at $24.63 on September 23, 2026, down from the previous session’s close of $24.70. The stock declined 1.12% over one week, compared with a $24.91 closing price on September 16, and was down 0.16% over one month from $24.67 on August 21.
The rating is separate from broader market consensus and target-price data. As of September 15, the consensus target stood at $29.43, with a median of $28.56. The mean target implied potential upside of 19.51% and represented a 0.49% reduction from the $29.58 mean recorded on August 28. As of September 1, analysts had issued 13 recommendations: three strong buys, six buys, three holds and one sell. Positive ratings accounted for 69.2% of the total, compared with 23.1% holds and 7.7% negative ratings. On August 1, the 12 recommendations comprised three strong buys, five buys, three holds and one sell, with positive ratings representing 66.7% of the total.
In its August 4, 2026 earnings report, Pacira reported EPS of $0.73, surpassing the estimated $0.6603 and delivering a 10.56% earnings surprise. Revenue came in at $192.399 million, below the estimated $194.633 million. Leerink Partners had also initiated coverage of the company on September 9 with a Market Perform rating.
Recent analyst actions
Recent analyst upgrades, downgrades, initiations and maintained ratings
| Date | Analyst | Prior Rating | Latest Rating | Action |
|---|---|---|---|---|
| September 23, 2026 | Oppenheimer | — | Outperform | Initiated coverage |
| September 9, 2026 | Leerink Partners | — | Market Perform | Initiated coverage |
Also Read
- Bank of America to Add 1,000 Apprentices and Inject $150M into Workforce Development
- Housebuilder Vistry slashes profit forecasts as losses balloon
- Netanyahu Addresses UN General Assembly Amid High Stakes Domestic Election and International Tensions
- Africa: UN Needs a Total Overhaul, Not Just Reforming Council
